Ankara Universitesi Teknokent   Report issue

Academic/Hospital Phase 3
Founded: Gölbaşı Turkey (2007)

Organization Overview

First Clinical Trial
2016
NCT04238858
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

Ankara Universitesi Teknokent | Zeynep Yurdakul

Active Ingredients

Drugs in Phase 3 Trials (1)

wharton's jelly mesenchymal stem cells (3 trials)

Drugs in Other Trials (1)

platelet-rich plasma (3 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Retinal Dystrophies (Phase 3)

Retinitis (Phase 3)

Retinitis Pigmentosa (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 6
  • # of Trial APIs: 2